Category Archives: Global
By Pharm Exec | Published: March 21, 2014
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Sylvant (siltuximab) for adult patients with multicentric Castleman’s disease.
By Guest Blogger | Published: March 14, 2014
The European pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery, writes Faiz Kermani. The European pharmaceutical industry accounts for nearly 40% of the global industry’s R&D investment. Although companies are responding to current pressures by closing R&D sites, they still need to support their ongoing drug-development projects […]
By Julian Upton | Published: March 13, 2014
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a social media campaign calling for an integrated life sciences strategy for the EU. The #HealthyEU Health and Growth campaign will outline the opportunities and threats faced by patients and the healthcare sector today, and provide evidence and facts to inform healthcare debates in the run […]
By Pharm Exec | Published: March 12, 2014
Japan’s schizophrenia treatment market value will see revenues doubling from $0.7 billion in 2012 to $1.4 billion by 2022 (a Compound Annual Growth Rate [CAGR] of 7.74%), says a new report from GlobalData.
By Pharm Exec | Published: March 7, 2014
The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital investments in biotechnology. According to research and consulting firm GlobalData, healthcare private equity investment in APAC increased by 125.8% between 2011 and 2013, whereas deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 […]